中国癌症杂志 ›› 2019, Vol. 29 ›› Issue (11): 906-909.doi: 10.19401/j.cnki.1007-3639.2019.11.010

• 综述 • 上一篇    下一篇

个体化肿瘤疫苗用于黑色素瘤治疗的研究进展

秦岚群 1 ,邹征云 2   

  1. 1. 南京医科大学鼓楼临床医学院肿瘤中心,江苏 南京 210008 ;
    2. 南京大学医学院附属鼓楼医院肿瘤中心,江苏 南京 210008
  • 出版日期:2019-11-30 发布日期:2019-12-11
  • 通信作者: 邹征云 E-mail: zouzhengyun001@163.com

Advances in personalized tumor vaccine for malignant melanoma

QIN Lanqun 1 , ZOU Zhengyun 2   

  1. 1. The Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, Jiangsu Province, China; 2. The Comprehensive Cancer Center, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China
  • Published:2019-11-30 Online:2019-12-11
  • Contact: ZOU Zhengyun E-mail: zouzhengyun001@163.com

摘要: 恶性黑色素瘤是一种恶性程度极高的肿瘤,虽发病率低,但易发生早期转移,死亡率高。中国黑色素瘤的发病率日趋增加且有年轻化趋势,已成为不可忽略的存在。近年来,个体化肿瘤疫苗的研究取得重大进展,有着广阔的应用前景。对目前个体化肿瘤疫苗在恶性黑色素瘤领域的研究进展进行综述。

关键词: 恶性黑色素瘤, 个体化肿瘤疫苗, 新抗原

Abstract: Malignant melanoma is a high-grade malignant tumor and prone to metastasis in early stage. Patients with advanced disease have poor prognosis. The incidence of melanoma in China is increasing day by day, and patients tend to be younger. In recent years, the research on personalized tumor vaccine has made great progress and has broad application prospects. In this paper, we reviewed the research progress of personalized tumor vaccine for malignant melanoma.

Key words: Malignant melanoma, Personalized tumor vaccine, Neoantigen